Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors

BACKGROUND: Citarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6, has demonstrated synergistic anticancer activity with paclitaxel in multiple solid tumor models. Combination therapy using citarinostat with paclitaxel was evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Michael S., Shapiro, Geoffrey I., Sarantopoulos, John, Juric, Dejan, Lu, Brian, Zarotiadou, Angeliki, Connarn, Jamie N., Le Bruchec, Yvan, Dumitru, Calin Dan, Harvey, R. Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779022/
https://www.ncbi.nlm.nih.gov/pubmed/35070991
http://dx.doi.org/10.3389/fonc.2021.786120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779022/
https://www.ncbi.nlm.nih.gov/pubmed/35070991
http://dx.doi.org/10.3389/fonc.2021.786120

Ejemplares similares